EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study)

Koshiro Nishimoto iD, Go Kimura, Tomokazu Sazuka iD, Shuzo Hamamoto, Masahiro Nozawa, Kazuyuki Numakura, Atsushi Mizokami, Tsunenori Kondo, Sei Naito iD, Takashige Abe iD, Kojiro Ohba iD, Masayoshi Nagata und 3 weitere

International Journal of Urology · 2025

DOI: 10.1111/iju.70076 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Koshiro Nishimoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Kidney Neoplasms, Ipilimumab. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Combination therapy of nivolumab‐plus‐ipilimumab has been approved for advanced or metastatic renal cell carcinoma in Japan, but large‐scale clinical data targeting Japanese patients is limited. To evaluate the early outcomes and factors related to early progression and response.

Methods

J‐ENCORE is an ongoing multicenter, prospective, observational study of the effectiveness and safety of nivolumab‐plus‐ipilimumab for patients in Japan with advanced or metastatic renal cell carcinoma. The objective response rate, duration of response, progression‐free survival, overall survival, incidence of adverse events, and factors related to early progression within 3 months, and response were assessed.

Results

We included 274 patients (median age: 68 years, 24.8% aged ≥ 75 years, 78.8% male). The median follow‐up was 23.4 months. The objective response rate was 36.8%. Among responders, 63.3% had progression‐free survival > 12 months. The median progression‐free survival was 9.9 months; the 12‐month overall survival was 76.3%. Of the patients, 77.0% experienced treatment‐related adverse events, 42.3% experienced grade 3–4 events, and 1.1% experienced treatment‐related death. Early progression was associated with female sex, poor risk status, liver metastasis, high baseline C‐reactive protein levels, and high neutrophil‐to‐lymphocyte ratios. Responders were less likely to have bone metastases. Limitations include the observational nature of the study and a relatively short follow‐up period.

Conclusions

This is the first prospective, real‐world study to demonstrate the effectiveness and safety of nivolumab‐plus‐ipilimumab in Japan, with the results comparable to those of CheckMate 214. These findings support the use of nivolumab‐plus‐ipilimumab, although further studies with longer follow‐up on nivolumab‐plus‐ipilimumab are needed. Trail Registration ClinicalTrials.gov identifier: NCT04043975; University Hospital Medical Information Network—Clinical Trial Registration: UMIN000036772.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellKidney NeoplasmsIpilimumabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedFemaleProspective StudiesJapanMiddle AgedProgression-Free SurvivalAged, 80 and overTreatment OutcomeAntineoplastic Agents, ImmunologicalAdultFollow-Up StudiesEast Asian People

Stichwörter der Autor:innen

Japanipilimumabnivolumabprospective studyrenal cell carcinoma

Substanzen

NivolumabIpilimumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
  • Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

ORCID-Profile: Koshiro Nishimoto, Tomokazu Sazuka, Sei Naito, Takashige Abe, Kojiro Ohba, Hirotsugu Uemura

Förderung

  • Bristol-Myers Squibb
  • Ono Pharmaceutical

Zitieren

APA

Nishimoto, K., Kimura, G., Sazuka, T., Hamamoto, S., Nozawa, M., Numakura, K., Mizokami, A., Kondo, T., Naito, S., Abe, T., Ohba, K., Nagata, M., Onodera, S., Ito, H., & Uemura, H. (2025). The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study). International Journal of Urology. https://doi.org/10.1111/iju.70076

Vancouver

Nishimoto K, Kimura G, Sazuka T, Hamamoto S, Nozawa M, Numakura K, et al. The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study). International Journal of Urology. 2025. doi:10.1111/iju.70076

BibTeX
@article{Nishimoto2025,
  author = {Nishimoto, Koshiro and Kimura, Go and Sazuka, Tomokazu and Hamamoto, Shuzo and Nozawa, Masahiro and Numakura, Kazuyuki and Mizokami, Atsushi and Kondo, Tsunenori and Naito, Sei and Abe, Takashige and Ohba, Kojiro and Nagata, Masayoshi and Onodera, Shunta and Ito, Hiroaki and Uemura, Hirotsugu},
  title = {The Effectiveness and Safety Profile of Nivolumab‐Plus‐Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J‐ ENCORE Study)},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70076}
}
Kostenlos starten →